» Articles » PMID: 18378950

The Case for Treating Tobacco Dependence As a Chronic Disease

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2008 Apr 2
PMID 18378950
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Smoking remains the leading cause of preventable death in the United States, yet it is still regarded by many as merely a bad habit. Most smokers want to quit but find it difficult. Behavioral counseling and pharmacotherapies are available, safe, and effective in the treatment of tobacco dependence. Nicotine replacement therapy effectively delivers nicotine in safer doses without exposure to the toxins and chemicals in cigarette smoke. The optimal duration of tobacco dependence treatment is unknown, and some smokers may require extended courses. For smokers using long-term cessation medications, health care providers should encourage treatment and insurance carriers should cover it. Both tobacco dependence and such conditions as diabetes are similar in their potential to exacerbate other diseases, their behavioral components of treatment, and their effectiveness of medications. Despite these similarities, treatments for diabetes are well covered by insurance, whereas tobacco dependence treatments are often limited. Tobacco dependence should share the status of other chronic illnesses, with effective treatments given as long as is necessary to achieve successful clinical outcomes.

Citing Articles

Association of Lifestyle Behaviors with Quality of Life in Patients with COPD: A Cross-Sectional Study in Primary Care.

Bouloukaki I, Christodoulakis A, Margetaki K, Tsiligianni I J Clin Med. 2024; 13(16).

PMID: 39200935 PMC: 11355864. DOI: 10.3390/jcm13164793.


Co-Designing a Smoking Cessation Chatbot: Focus Group Study of End Users and Smoking Cessation Professionals.

Bendotti H, Lawler S, Ireland D, Gartner C, Marshall H JMIR Hum Factors. 2024; 11:e56505.

PMID: 39159451 PMC: 11369547. DOI: 10.2196/56505.


An Introduction and Practical Guide to Strategies for Analyzing Longitudinal Data in Clinical Trials of Smoking Cessation Treatment: Beyond Dichotomous Point-Prevalence Outcomes.

Kypriotakis G, Bernstein S, Bold K, Dziura J, Hedeker D, Mermelstein R Nicotine Tob Res. 2024; 26(7):796-805.

PMID: 38214037 PMC: 11190044. DOI: 10.1093/ntr/ntae005.


Obstructive Sleep Apnea and Smoking Increase the Risk of Cardiovascular Disease: Smoking Cessation Pharmacotherapy.

Pataka A, Kotoulas S, Karkala A, Tzinas A, Kalamaras G, Kasnaki N J Clin Med. 2023; 12(24).

PMID: 38137639 PMC: 10743586. DOI: 10.3390/jcm12247570.


Introducing Quin: The Design and Development of a Prototype Chatbot to Support Smoking Cessation.

Bendotti H, Ireland D, Lawler S, Oates D, Gartner C, Marshall H Nicotine Tob Res. 2023; 26(5):612-620.

PMID: 37936253 PMC: 11033568. DOI: 10.1093/ntr/ntad217.